1. Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study
- Author
-
Simon M. McHugh, Paul W. Thompson, Frank A Gray, Onajite Kousin-Ezewu, Jenny L Craigen, Disala Fernando, Alasdair Coles, Donggang Su, Joanne Ellis, Keguan Chen, Sara Santos Franco, Joao-Joaquim Oliveira, Kim Brown, Lea Fortunato, André van Maurik, Ann M. Schwartz, Sophie Gisbert, Jiansong Yang, Sara Brett, Bill Davis, Joseph Cheriyan, Andrew Want, and Jeffrey Price
- Subjects
Adult ,Male ,drug safety ,Adolescent ,medicine.medical_treatment ,T cell ,T-Lymphocytes ,Pharmacology ,Antibodies, Monoclonal, Humanized ,030226 pharmacology & pharmacy ,Autoimmune Diseases ,immunology ,Interleukin-7 Receptor alpha Subunit ,Placebos ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Pharmacokinetics ,Double-Blind Method ,medicine ,pharmacodynamics ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Interleukin-7 receptor ,Receptor ,Infusions, Intravenous ,Aged ,biology ,business.industry ,Interleukin ,Original Articles ,Middle Aged ,Healthy Volunteers ,Cytokine ,medicine.anatomical_structure ,Pharmacodynamics ,biology.protein ,Original Article ,Female ,monoclonal antibodies ,Antibody ,business ,pharmacokinetics ,Half-Life - Abstract
Aim Interleukin (IL)-7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study investigated the safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of GSK2618960, an IL-7 receptor-α subunit (CD127) monoclonal antibody. Methods A double-blind (sponsor-unblind) study of a single intravenous infusion of either GSK2618960 (0.6 mg kg-1 or 2.0 mg kg-1 ) or placebo was carried out in 18 healthy subjects over 24 weeks. Results GSK2618960 was well tolerated; there were no serious or significant adverse events. The observed half-life was 5 (±1) days (2.0 mg kg-1 ), with nonlinear pharmacokinetics. Full receptor occupancy (>95%) was observed until day 8 (0.6 mg kg-1 ) and day 22 (2.0 mg kg-1 ). Maximal inhibition of IL-7-mediated signal transducer and activator of transcription 5 (STAT5) phosphorylation was observed in 5/6 subjects until day 22 (2.0 mg kg-1 ). Mean circulating IL-7 and soluble receptor (CD127) levels were increased above baseline during days 2 and 15 (0.6 mg kg-1 ) and days 2 and 22 (2.0 mg kg-1 ). No meaningful changes were observed in absolute numbers or proportions of immune cell populations or inflammatory cytokine profiles (IL-6, tumour necrosis factor-α, interferon-γ, IL-2). Persistent antidrug antibodies (ADAs) were detected in 5/6 subjects administered a dose of 0.6 mg kg-1 (neutralizing in 2/6) and in 6/6 subjects administered 2.0 mg kg-1 (neutralizing in 5/6). Conclusion GSK2618960 was well tolerated and blocked IL-7 receptor signalling upon full target engagement. Although there was no discernible impact on peripheral T cell subsets in healthy subjects, GSK2618960 may effectively modulate the autoinflammatory activity of pathogenic T cells in diseased tissue. A relatively short half-life is likely the result of target-mediated rather than ADA-mediated clearance.
- Published
- 2018